Biora Therapeutics Inc.
| NASDAQ: BIOR | Healthcare / Biotechnology / USA |
| 1.15 | -0.0200 | -1.71% | Vol 382.59K | 1Y Perf -78.25% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 1.14 | ASK | 1.19 | ||
| Open | 1.18 | Previous Close | 1.17 | ||
| Pre-Market | - | After-Market | 1.18 | ||
| - - | 0.03 2.61% |
| Target Price | 150.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 12.94K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.28 | Earnings Rating | — | |
| Market Cap | 27.26M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.07 | Standard Deviation | 0.37 | |
| Beta | 0.94 |
Today's Price Range 1.121.21 | 52W Range 1.137.68 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.31% | ||
| 1 Month | -31.58% | ||
| 3 Months | -61.89% | ||
| 6 Months | -74.45% | ||
| 1 Year | -78.25% | ||
| 3 Years | -98.57% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 94.85 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -161.40 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| - | ||||
| 64.73 | ||||
| - | ||||
| -0.30 | ||||
| -12.95 | ||||
| -0.18 | ||||
| -10.92 | ||||
| 110.66M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.40 | ||||
| 1.70 | ||||
| - | ||||
| - | ||||
| -21.20 | ||||
| Leverage Ratio | -0.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 100.00 | ||||
| -8 304.00 | ||||
| -8 149.40 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 291.00K | ||||
| 0.03 | ||||
| -69.96 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.93 | -0.75 | 19.35 |
| Q02 2023 | -1.60 | -1.47 | 8.12 |
| Q01 2023 | - | -1.59 | - |
| Q04 2022 | -0.89 | -1.61 | -80.90 |
| Q03 2022 | -1.50 | -2.00 | -33.33 |
| Q02 2022 | -3.25 | -0.75 | 76.92 |
| Q01 2022 | -3.00 | -3.00 | 0.00 |
| Q04 2021 | -3.25 | -5.25 | -61.54 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.93 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 382.59K |
| Shares Outstanding | 23.70K |
| Shares Float | 11.49M |
| Trades Count | 2.17K |
| Dollar Volume | 447.24K |
| Avg. Volume | 1.38M |
| Avg. Weekly Volume | 2.89M |
| Avg. Monthly Volume | 869.59K |
| Avg. Quarterly Volume | 377.02K |
Biora Therapeutics Inc. (NASDAQ: BIOR) stock closed at 1.17 per share at the end of the most recent trading day (a -6.4% change compared to the prior day closing price) with a volume of 626.57K shares and market capitalization of 27.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 124 people. Biora Therapeutics Inc. CEO is Aditya P. Mohanty.
The one-year performance of Biora Therapeutics Inc. stock is -78.25%, while year-to-date (YTD) performance is -64.46%. BIOR stock has a five-year performance of %. Its 52-week range is between 1.1315 and 7.68, which gives BIOR stock a 52-week price range ratio of 0.28%
Biora Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 64.73, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -161.40%, a ROC of -% and a ROE of 94.85%. The company’s profit margin is -%, its EBITDA margin is -8 149.40%, and its revenue ttm is $291.00 Thousand , which makes it $0.03 revenue per share.
Of the last four earnings reports from Biora Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Biora Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Biora Therapeutics Inc. is Strong Buy (1), with a target price of $150, which is +12 943.50% compared to the current price. The earnings rating for Biora Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biora Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biora Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 62.37, ATR14 : 0.16, CCI20 : -130.97, Chaikin Money Flow : -0.39, MACD : -0.18, Money Flow Index : 79.70, ROC : -9.30, RSI : 31.32, STOCH (14,3) : 8.05, STOCH RSI : 0.37, UO : 30.92, Williams %R : -91.95), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biora Therapeutics Inc. in the last 12-months were:
Biora Therapeutics Inc.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.
CEO: Aditya P. Mohanty
Telephone: +1 855 293-2639
Address: 4330 La Jolla Village Drive, San Diego 92122, CA, US
Number of employees: 124
